Drugs / Befotertinib
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07458919 | Mar 2026 → Oct 2030 expected | lung cancer | Fuzhou General Hospital | Not yet recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06015568 | Sep 2023 → Nov 2028 expected | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04464551 | Dec 2020 → Aug 2021 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03452150 | Jan 2018 → Aug 2020 | non-small cell lung carcinoma | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07410611 | Feb 2026 → Feb 2030 expected | non-small cell lung carcinoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07181499 | Sep 2025 → Nov 2028 expected | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06863506 | Oct 2024 → Jun 2027 expected | non-small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06517953 | Jul 2024 → Jul 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05007938 | Aug 2021 → Dec 2024 overdue | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03861156 | Feb 2019 → Aug 2021 | non-small cell lung carcinoma | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04206072 | Dec 2019 → Jul 2022 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06041776 | Mar 2023 → Apr 2028 expected | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06755684 Background | Nov 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Peng Zhang | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06561620 Comparator | May 2024 → May 2027 expected | — | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Befotertinib | “Befotertinib (D-0316) is a novel, selective oral third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor.” PMID 37244266 ↗ May 202311“Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI).” PMID 35724798 ↗ Jun 2022 “Befotertinib: Oral administration, taken on an empty stomach or with food.” NCT07458919 ↗ |
| Known as | D-0316 | “Befotertinib (D-0316) is a novel, selective oral third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor.” PMID 37244266 ↗ May 20234“Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI).” PMID 35724798 ↗ Jun 2022 “Drug:Befotertinib (75 mg or 100 mg orally, once daily) Other name:D-0316” NCT06015568 ↗ |
| Action | Inhibit | “EGFR mutant-selective inhibitor” PMID 35274722 ↗ Mar 2022 |
| Modality | Small molecule | “Befotertinib (D-0316) is a novel, selective oral third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor.” PMID 37244266 ↗ May 2023 |
| Route | Oral | “daily oral D-0316 administration” PMID 35274722 ↗ Mar 2022 |
| Target | EGFR | “Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI).” PMID 35724798 ↗ Jun 2022 |